Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Digoxin × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 6 Tumor-Agnostic 4 Gastrointestinal 4 Breast 4 Thoracic 3 Dermatologic 3 Head & Neck 2 Genitourinary 2 Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Endocrine 1 CNS 1

Conditions

Medulloblastoma 1

Interventions

Temozolomide 620 Radiotherapy 409 Bevacizumab 254 Magnetic Resonance Spectroscopy 223 Cyclophosphamide 178 Radiosurgery 162 Carboplatin 160 Etoposide 132 Radiation 128 Vincristine 115 Irinotecan 115 Cisplatin 103 Filgrastim 100 Specimen Handling 89 Nivolumab 88 pembrolizumab 83 Surgical Procedures, Operative 83 Lomustine 82 Topotecan 72 Doxorubicin 60 Melphalan 59 Carmustine 57 Radiotherapy, Intensity-Modulated 55 sargramostim 53 Isotretinoin 53 Peripheral Blood Stem Cell Transplantation 52 Granulocyte Colony-Stimulating Factor 51 Chemotherapy, Adjuvant 51 Erlotinib Hydrochloride 50 Blood Specimen Collection 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06701812 2026-02-27

Digoxin Medulloblastoma Study

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting

Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡